Alofisel▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

18.02.2022 - Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, ...

Related Keywords

Alofi ,Niue General ,Niue ,Japan ,United States ,United Kingdom ,Israel ,Switzerland ,Tel Aviv ,Israeli ,Elisabeth Genestin ,Van Assche ,Oded Zmora ,Injektion Darvadstrocelum ,Ann Gastroenterol ,Takeda Pharmaceuticals United States Inc ,Admire Cd Study Group Collaborators ,Senior Global Brand Medical Affairs ,Takeda Pharmaceutical Company Ltd ,Takeda Pharmaceutical Company ,European Union Economic Area ,European Union ,Takeda Pharmaceutical Company Limited ,Japan Pharmaceuticals ,European Network Of Centres ,Department Of Surgery ,Ministry Of Health Israel ,Exchange Commission ,Shamir Medical Center ,Devices Agency ,Bradshaw Index ,Professor Oded Zmora ,Rectal Surgeon ,Shamir Medical ,Senior Global Brand Medical Affairs Director ,Regenerative Medicine Advanced Therapy ,European Economic Area ,Product Characteristics ,Rare Genetics ,Plasma Derived Therapies ,Pharmaceutical Company Limited ,Annual Report ,European Network ,Medical Devices ,Products Approved ,Regenerative Medical ,Israeli Drug ,Pharmaceutical Company ,Pharmaceuticals United States ,Drug Evaluation ,Takeda Logo ,Takeda Yakuhin Kogyo ,